Berkeley Lights (BLI) is arguably the most attractive pure-play company in the cell-based product ma...
Bristol-Myers: A Strong Buy for Growth & Income
05/22/2020 5:00 am EST
Bristol-Myers Squibb Company (BMY) is a biopharmaceutical company with a mission to discover, develop and deliver innovative medicines that help patients prevail over serious diseases, asserts Crista Huff, editor of Cabot Undervalued Stocks Advisor.
Bristol-Myers purchased Celgene for $74 billion in November 2019. The merged company markets a long list of pharmaceuticals, including Revlimid, Eliquis and Opdivo, to treat cardiovascular, oncology and immunological diseases.
The company expects revenue and profit growth to come from four areas: sales volume increases from current products, development and launch of new medicines, life cycle management and synergies from the Celgene acquisition.
Bristol-Myers announced that Opdivo in combination with Yervoy was approved by the FDA for the first-line treatment of a specific group of adult patients with metastatic non-small cell lung cancer (NSCLC).
The company also announced FDA approval of Pomalyst for patients with AIDS-related Kaposi sarcoma whose disease has become resistant to highly active antiretroviral therapy (HAART), or in patients with Kaposi sarcoma who are HIV-negative. Pomalyst was granted accelerated approval, Breakthrough Therapy designation and Orphan Drug designation.
The company is expected to increase EPS by 32% and 20% in 2020 and 2021, and the 2020 P/E is 10.4. Bristol-Myers’ financial priorities include debt repayment, investment in innovation, share repurchases and annual dividend increases.
I would expect earnings growth to slow in subsequent years as the company digests the Celgene merger and business grows at a more normal pace. Bristol-Myers is appropriate for growth investors and income investors. With a yield of 2.8%, the stock is rated a "Strong Buy" in our growth and income model portfolio.
Related Articles on HEALTHCARE
Progenity (PROG) is a diagnostic testing company focused primarily on women’s health, explains...
Gilead Sciences (GILD) is under severe pressure and many investors don’t think it’ll eve...
The most advanced clinical programs at Precigen (PGEN) — known as PRGN-3005 UltraCAR-T and PRG...